ArticleRadiation oncology (London, England)2025
Sex-based differences in patients with locally advanced pharyngeal and laryngeal SCC treated with definitive or adjuvant radiotherapy.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surgery followed by adjuvant radiotherapy versus definitive radiotherapy for locally advanced squamous cell carcinoma of the pharynx and larynx: a propensity score-matched analysis.Clinical and translational radiation oncology · 2027Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate sex-based differences in survival outcomes, toxicity, and patterns of local recurrence in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive or adjuvant radiotherapy (RT).
methodsWe conducted a retrospective review of 309 patients (246 males, 63 females) diagnosed with primary squamous cell carcinoma of the oropharynx, larynx, or hypopharynx treated with curative-intent RT at our institution between 2016 and 2023. Inclusion criteria comprised histologically confirmed SCC, stage T3/T4 and/or node-positive disease, and complete RT treatment with adequate follow-up. Survival endpoints-overall survival (OS), progression-free survival (PFS), and metastasis-free survival (MFS)-were analyzed using the Kaplan-Meier method and log-rank tests. Patterns of local failure were classified using an established five-type system: A (central high-dose), B (peripheral high-dose), C (central intermediate- or low-dose), D (peripheral intermediate- or low-dose), and E (extraneous dose). Treatment-related toxicity was also compared between sexes.
resultsNo significant differences in OS, PFS, or MFS were found between male and female patients across all treatment subgroups. Log rank test did not identify any significant prognostic factor for survival and local recurrence. However, female patients experienced a higher rate of grade ≥ 3 dermatitis (12.7% vs. 5.3%, p = 0.037). Pattern A nodal failures (central high-dose volume) were significantly more common in females (64.3%) than in males (28.8%; p = 0.014), while other recurrence patterns showed no significant sex-based differences.
conclusionSex was not an independent predictor of survival in this cohort of locally advanced HNSCC patients. Nevertheless, the higher rate of severe skin toxicity and nodal failures in females highlights a potential need for sex-adapted radiotherapy strategies and further prospective investigation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.